SCHEMBL13429004

SCHEMBL13429004

O=c1cc(Oc2ccc(-c3ccc(F)cc3)cc2)c2ccccc2[nH]1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSV O60911 1/20 0.50
CTSL P07711 1/20 0.50
TNKS2 Q9H2K2 2/20 0.47
KDM4E B2RXH2 6/20 0.47
ALDH1A1 P00352 5/20 0.47
HTT P42858 2/20 0.47
GLA P06280 1/20 0.47
GAA P10253 1/20 0.47
HPGD P15428 4/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
MAPK1 P28482 1/20 0.45
CYP1A2 P05177 1/20 0.44
CYP2C19 P33261 1/20 0.44
MAPK14 Q16539 1/20 0.42
TUBB4A P04350 2/20 0.42
TUBB P07437 2/20 0.42
TUBA3C P0DPH7 2/20 0.42
TUBA1B P68363 2/20 0.42
TUBA4A P68366 2/20 0.42
TUBB4B P68371 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13429066 0.96 KDM4E (0.50) CTSVCTSLTNKS2KDM4EALDH1A1
SCHEMBL13429113 0.90 HPGD (0.57) CTSVCTSLTNKS2KDM4EALDH1A1
SCHEMBL13429118 0.86 HPGD (0.45) TNKS2KDM4EALDH1A1HTTGAA
SCHEMBL13429178 0.85 HPGD (0.44) TNKS2KDM4EALDH1A1HTTHPGD
SCHEMBL2008835 0.84 HPGD (0.54) TNKS2KDM4EALDH1A1HTTGLA
SCHEMBL13429036 0.82 HPGD (0.46) CTSVCTSLTNKS2KDM4EALDH1A1
SCHEMBL13429125 0.82 TUBB4A (0.42) TNKS2KDM4EALDH1A1HTTGAA
SCHEMBL13429120 0.82 TUBB4A (0.43) TNKS2KDM4EALDH1A1HTTGAA
SCHEMBL13429166 0.82 AKT1 (0.43) TNKS2KDM4EALDH1A1HTTHPGD
SCHEMBL13429176 0.82 KDM4E (0.46) TNKS2KDM4EALDH1A1HTTGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100068204-A1 4-ARYLOXYQUINOLIN-2(1H)-ONES AS MTOR KINASE AND PI3 KINASE INHIBITORS, FOR USE AS ANTI-CANCER AGENTS WYETH (US) 2010-03-18 US disclosed
US-20100068204-A1 4-ARYLOXYQUINOLIN-2(1H)-ONES AS MTOR KINASE AND PI3 KINASE INHIBITORS, FOR USE AS ANTI-CANCER AGENTS WYETH (US) 2010-03-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100068204-A1 4-ARYLOXYQUINOLIN-2(1H)-ONES AS MTOR KINASE AND PI3 KINASE INHIBITORS, FOR USE AS ANTI-CANCER AGENTS MTOR, RICTOR, PIK3CA CTSV 3420/4885CTSL 4192/4885TNKS2 487/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.